MethylDetect

Executive Summary

MethylDetect is a Danish biotechnology company founded in 2019 that has developed ready-to-use DNA methylation detection assays based on Methylation Sensitive High Resolution Melting (MS-HRM) technology. Its products are designed for use with standard laboratory equipment, enabling researchers in diagnostics, genetics, and genomics to perform epigenetic analysis for various diseases without specialized instruments. The company’s initial focus is on providing cost-effective and accessible tools for methylation analysis, which is increasingly recognized as a key biomarker for cancer, rare diseases, and developmental disorders. MethylDetect’s assays target the growing demand for epigenetic diagnostics, offering a simpler alternative to methods like bisulfite sequencing or methylation-specific PCR. As a private, early-stage company with limited public information, MethylDetect faces the challenge of scaling its product portfolio and establishing a commercial footprint in the competitive diagnostics market. Its technological differentiation lies in the use of MS-HRM, a method that is both sensitive and compatible with common qPCR platforms. The company is likely to generate initial revenue through direct sales to academic and clinical research labs in Europe, with potential for expansion through licensing or partnerships. Given the nascent stage and lack of disclosed funding, execution risk remains high, but the epigenetic diagnostic space offers substantial growth opportunities if the company can validate its technology and secure strategic collaborations.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of first ready-to-use MS-HRM assay panel60% success
• Q2 2026CE-IVD mark for flagship methylation assay50% success
• H2 2026Partnership or distribution agreement with European diagnostic supplier40% success